Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Nan Bi
Application of Artificial Intelligence Advances in Athletics Industry: A Review
References 1, , , and , “Artificial Intelligence and Machine-Learning Approaches in Sports: Concepts, Applications, Challenges, and Future Perspectives,” Brazilian Journal of Physical Therapy 28 (2024): 101083. 2, , , , , and , “Generating Medical Report via Joint Probability Graph Reasoning,” Tsinghua Science and Technology (2024), https://doi.org/10.26599/TST.2024.9010058.
Induction and concurrent aumolertinib with radiotherapy for EGFR -mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation
Abstract The phase III ADVANCE study prospectively assessed a chemotherapy-free strategy combining aumolertinib with definitive radiotherapy (RT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations (ChiCTR.org: ChiCTR2000040590). Participants were assigned in a 1:1 ratio to either the experimental arm (110 mg daily aulomertinib plus RT) or the control arm (cisplatin/pemetrexed with RT).
Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer (ES‐SCLC): Study protocol - Deng - Thoracic Cancer - Wiley Online Library
INTRODUCTION Approximately 13% of lung cancer cases are small cell lung cancer (SCLC), which is also thought to be a 4% cause of cancer-related death.1, 2 At the time of the initial diagnosis, 70% of patients are already in the extensive stage, and median overall survival (OS) is only 8–10 months.3, 4 Platinum-based chemotherapy remains the mainstay treatment for advanced stage small cell lung cancer (ES-SCLC), with response rates ranging from 60% to 80%.2 However, approximately 90% of...
Interleaved online testing in large-scale systems
Online testing is indispensable in decision making for information retrieval systems. Interleaving emerges as an online testing method with orders of magnitude higher sensitivity than the pervading A/B testing. It merges the compared results into a single interleaved result to show to users, and attributes user actions back to the systems being tested.
Frontiers | Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
1 Introduction According to GLOBOCAN 2022 (1), lung carcinoma is the most common malignant tumor and a major reason for cancer-related deaths worldwide. Almost 75% of lung cancers are non-small cell lung cancer (NSCLC), while 70% of them were already in the advanced stages at the time of diagnosis. Lung squamous cell carcinoma (LUSC) is an important pathological type of NSCLC, accounting for approximately 30% of all lung cancer patients.
Cancers | Free Full-Text | Radiotherapy Fraction in Limited-Stage Small Cell Lung Cancer in the Modern Era: A Systematic Review and Meta-Analysis of 8006 Reconstructed Individual Patient Data
Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
Debiased balanced interleaving at Amazon Search
Interleaving is an online evaluation technique that has shown to be orders of magnitude more sensitive than traditional A/B tests. It presents users with a single merged result of the compared rankings and then attributes user actions back to the evaluated rankers. Different interleaving methods in the literature have their advantages and limitations with respect to unbiasedness, sensitivity, preservation of user experience, and implementation and computation complexity.
Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC
We applaud Qing Zhou and colleagues for reporting the results of the GEMSTONE-301 phase 3 trial investigating sugemalimab after chemoradiotherapy for locally advanced non-small-cell lung cancer (NSCLC) in The Lancet Oncology. 1 Zhou Q Chen M Jiang O et al.
External Validation of the Eighth Edition of the TNM Classification for Lung Cancer in Small Cell Lung Cancer
Highlights • The eighth edition of the TNM classification showed improved prognostic accuracy compared with the seventh edition in SCLC. • Patients with N3 contralateral supraclavicular nodes had a significantly worse prognosis than those without. • For patients with single-site metastasis, liver involvement showed a worse prognosis compared to brain involvement.
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial | Clinical Pharmacy an
Key Points español 中文 (chinese) Question Could selective cyclooxygenase 2 inhibition combined with standard concurrent chemoradiation therapy improve survival among patients with unresectable stage III non–small cell lung cancer? Findings In this phase 2 clinical trial of 96 patients, adding celecoxib to concurrent chemoradiation did not improve survival. Meaning Adding celecoxib to concurrent chemoradiation did not improve survival.
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases
Advertisement Advertisement Nan Bia, Yuchao Maa, Jianping Xiao (jpxiao8{at}163.com)*,a, Hongmei Zhangb, Yingjie Xua, Yuan Tiana, Junling Lic, Ye Zhanga, Qingfeng Liua, Kai Wanga, Lei Denga, Wenqing Wanga, Xuesong Chena, Feng Liua, Ruizhi Zhaoa, Siran Yanga, Xiaodong Huanga, Junlin Yia, Chen Hud and Yexiong Lia a Department of Radiation Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China b Department of Radiology, Chinese Academy...
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases
Nan Bia, Yuchao Maa, Jianping Xiao (jpxiao8{at}163.com)*,a, Hongmei Zhangb, Yingjie Xua, Yuan Tiana, Junling Lic, Ye Zhanga, Qingfeng Liua, Kai Wanga, Lei Denga, Wenqing Wanga, Xuesong Chena, Feng Liua, Ruizhi Zhaoa, Siran Yanga, Xiaodong Huanga, Junlin Yia, Chen Hud and Yexiong Lia a Department of Radiation Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China b Department of Radiology, Chinese Academy of Medical Sciences and...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Nan
Contact Nan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack